Background: Intranasal corticosteroids (INCS) are prescribed for the long-term prophylactic treatment of inflammatory upper
Introduction
The intranasal corticosteroids (INCS) are prescribed in the management of upper airway inflammation. With their well-known anti-inflammatory properties, they provide relief for rhinitis symptoms, decongest airway oedema, restore nasal breathing, decrease mucus production and reduce the recurrence rates of upper airway inflammation (1, (4) (5) (6) . Therefore, INCS are recommended in many evidence-based guidelines, for the management of upper airway disease (7, 8) .
Adverse effects of intravenous, oral and inhaled steroids following systemic absorption are well established (1) (2) (3) . In recent years, the development of molecules designed to achieve potent, localized activity on nasal mucosa with minimal risk of systemic exposure. Patients are able to benefit from the therapeutic effects of the corticosteroids, while minimizing the use of steroid therapy via other routes (9) .
C o r r e c t e d p r o o f
In recent years there have been an increasing number of case reports and case series frequently citing INCS as a contributing factor to ocular adverse effects, challenging their role as a safer option (10) (11) (12) . Although it has long been recognised that a high dose inhaled corticosteroids can lead to systemic adverse effects, including the risk of developing ocular hypertension or open-angle glaucoma (1, 13) , there has been little indication of such risk with intranasal administration. The ability of INCS to cause adverse systemic effects is mediated via nasal mucosa, or the gastrointestinal tract absorption. The newer generations of intranasal steroids are not only highly lipophilic, but also undergo rapid and extensive first-pass metabolism following ingestion; and therefore, have negligible systemic absorption from the latter route. Systemic bioavailability of drugs such as mometasone furoate or fluticasone propionate is as low as 0.1%, and less than 2%, respectively. This compares favorably to older generation of INCS, where one-third to half of an intranasal dose can reach the systemic circulation. Additionally, compared to inhaled corticosteroids, nasal steroids are usually administered in much smaller doses with more limited contribution to the systemic circulation (4, 9, 13, 14) . Hence, the systemic effect of INCS, and its adverse clinical impact remain controversial.
In recent years, there have been published case reports and series, reporting changes in intraocular pressure or lens opacity in those consuming INCS (11) (12) (13) . However, few higher-level studies are cited when discussing ocular effects from INCS. Narrative reviews have the potential for bias in their summaries when not systematic in the review of the literature. Therefore, the aim of this study is to systematically review the evidence of the effect of INCS on potential adverse ocular effects.
Materials and methods
A systematic review was performed to identify published manuscripts with original data on any ocular effects from the use of INCS. PRISMA guidelines (23) and recommendations from the Cochrane Handbook of Systematic reviews were followed where possible.
Databases searched
The electronic databases were used to conduct the search. The bibliographies of studies subject to full-text analysis was reviewed and used as a further data source.
Search strategy
A search strategy was constructed using a combination of medical subject headings and keywords relevant to nasal and sinus disease as well as intranasal steroids. The search strategy used to search the electronic databases, Embase, and Medline databases are shown in Table 1 .
Study selection
Study selection was performed by two authors (NA and RJH) in an unblended standardized manner. The following steps were taken. The identified publications from the electronic databases were combined. The lists of identified publications were scanned using PRISMA guidelines (15) , shown in Figure 1 . Non-English, non-human studies, and duplicate publications were identified and removed.
The publications extracted were then further scanned using a combination of abstract or full-text. Those, which failed to use steroid as a treatment, apply it exclusively intranasal, nor reported original data of intraocular pressure or lens opacity were excluded.
The publications extracted were grouped by title review into studies that are case reports, literature reviews or comparative studies. The two former were excluded and the later was further included for qualitative synthesis.
Criteria for included studies

Type of studies
Any studies on population of patients using INCS were included.
Randomized controlled trials (RCTs), cohorts, case-control and case series were caught. Simple case reports were not included. 
C o r r e c t e d p r o o f
The title and abstract screen of the references identified 216 (44.6%) studies that did not use corticosteroids, 20 (4.1%) that either failed to apply the steroid intranasally or failed to avoid oral, inhaled or intravenous steroids as co-intervention, and 111 (23.0%) of the studies that failed to report original data on intraocular pressure, lens opacity or incidence of glaucoma or cataract. The full text analysis of the remaining 137 studies identified 116 (84.7%) studies that were literature reviews, and 2 (1.5%) case reports. Nineteen (n = 19) (13.9%) studies were included.
Included studies
Of these 19 included studies, 9 reported data outcome on IOP (3, 6, 11, 13, (20) (21) (22) (23) (24) , 1 on lens opacity (25) , and 9 studies reported data on both IOP and lens opacity (14, (26) (27) (28) (29) (30) (31) (32) (33) . This then left 18 (94.7%) (3, 6, 11, 13, 14, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) studies on IOP, and 10 (55.6%) (14, (25) (26) (27) (28) (29) (30) (31) (32) (33) ) on lens opacity in clearly defined patient groups that could be used for comparison in this systematic review (14, (26) (27) (28) (29) (30) (31) (32) (33) . The study characteristics of the 19 included manuscripts are described in Tables 4 and   5 . Studies followed the standard practices. The diagnosis of glaucoma was either based on the degree of increase in IOP (>10mmHg or >20% from the baseline) or the measure of IOP alone (>20mmHg). The same process was followed in measuring the lens opacity, whereby the diagnosis was made by a qualified ophthalmologist in accordance to a rigid set of guidelines. This involved slit lamp examination and refractometer.
Intraocular pressure and INCS
Of the 19 studies included in this review, 18 (94.7%) reported outcomes on IOP, but only 11 (63.2%) (1, (20) (21) (22) (23) (26) (27) (28) (29) (30) (31) had a control group. These studies included 10 RCTs (57.9%) (6, (20) (21) (22) (23) (26) (27) (28) (29) (30) (31) and one case-control study (1) .
Of the eleven RCTs, three (n = 3) assessed children aged between 2 to 11 years old (28) (29) (30) , three (n = 3) on children (>12 years old) and adults (26, 27, 31) , and four (n = 4) on adults between 18 to 65 years of age (20) (21) (22) (23) . The case control study included both children and adults population (1) . Majority of the comparative studies were conducted on individuals with Seasonal (SAR) or Perennial (PAR) Allergic Rhinitis for at least 6 months and positive skin prick test, who were exclusively being treated with no other form of delivery method of steroids other than intranasal.
One study (22) was conducted on postoperative FESS patients; and the case-control study (1, 3) was conducted on individuals with glaucoma and ocular hypertension who were also happen to be on intranasal corticosteroids. All studies except four (n = 4) (22, 23, 29, 30) . RCTs excluded individuals with glaucoma or ocular hypertension. The comparative studies included in this systematic review, together report on the effect of a variety of intranasal steroids including Fluticasone, Mometasone, Beclomethasone, Ciclesonide, and Budesonide. Almost all studies reported spe-
Types of participants
Adults and children with either, allergic rhinitis, (seasonal or perennial or moderate-severe persistent allergic rhinitis) confirmed by skin prick testing or in-vitro test for an allergen specific IgE or CRS as defined by either European Position Paper on Rhinosinusitis and Nasal polyps 2007 (16) , or Rhinosinusitis Task Force Report (17) and its revision (18) were included.
Types of interventions
Studies involving topical steroid therapies versus either placebo, no treatment or another topical steroid therapy were considered. Trials using any co-interventions of oral steroid, antihistamines, decongestants, antibiotics (topical or intravenous) were included when the co-interventions were equally applied in both groups.
Outcome measures
All outcomes reporting changes or abnormality in IOP, visual acuity, cup to disc ratio, ocular hypertension, or the detection, and or alteration of known glaucoma were assessed. Additionally, any change relating to, cataract or measurements of lens opacity were also included.
Exclusion criteria
Any study that did not report an outcome of IOP, glaucoma assessment, lens opacity or cataract assessment. Case reports
only. An exogenous corticosteroid taken either topically, inhaled or orally when not applied equally between controls and INCS users.
Risk of bias
Risk of bias in randomized controlled trials was assessed at a study level using the Cochrane Risk of Bias Assessment Tool (19) .
Statistical analysis
Statistical analyses were performed using SPSS v 20.0 (Statistical Package for the Social Sciences, Chicago, IL, USA). Data was presented as descriptive statistics only. Parametric scale data was described with mean and standard deviation. Nonparametric data is described with median and interquartile range (IQR).
Where, no IQR was provided, absolute range was recorded.
Results
The search produced a total of 660 studies. The first-level screening removed 107 irrelevant studies or duplicates, 40 nonEnglish, and 34 studies where the subjects were not human. The flowchart of the study selection using PRISMA flowchart (15) is provided in Figure 1 . All 479 remaining abstracts were reviewed to assess if they met the inclusion criteria. An additional 5 studies were identified from bibliographic search from reviewed articles, brining the total of the studies to 484 to be screen. cific tools such as tonometry in addition to detailed physician examination in collecting the intraocular pressure measurements; and defined the measures considered abnormal prior to commencing the study. The outcomes were either reported as detailed measures of changes in IOP (continuous), and/or presence or absence of glaucoma (dichotomous).
C o r r e c t e d p r o o f
The study outcomes for intraocular pressure and occurrence of glaucoma are described in Table 4 Table 5 . Results of the included studies investigating lens opacity (LO) or the formation of cataracts. Table 6 . Outcome of case reports and case series -intraocular pressure or lens opacity.
PSC: Posterior subcapsular cataract objective standard tools by a physician trained to examine the eye. The selected abnormal measures for IOP range from >21 to >25mmHg. Almost all outcomes reported were dichotomous.
And all studies, including the studies that did not exclude patient with pre existing intraocular hypertension or glaucoma (3, 22, 23, 29, 30) , reported no significant additional increase in IOP or occurrence of glaucoma in the INCS arm.
Lens opacity and INCS
Ten out of the 19 (52.6%) (14, (25) (26) (27) (28) (29) (30) (31) (32) (33) studies included for qualitative analysis reported outcome on lens opacity, but only 6 (31.6%) (26) (27) (28) (29) (30) (31) studies were randomised control studies. In contrast to the studies reporting on IOP, all studies included children in their selected population. Three studies included patients above twelve years of age (26, 27, 31) , and three (n = 3) included children between the ages of two to eleven (28) (29) (30) . In all studies, the patient population suffered from PAR or SAR for at least 6 months and had a positive skin prick test. All studies excluded patients with known glaucoma or cataract. The studies were conducted for minimum of 6 weeks to a maximum of 2 years. In contrast to the studies on IOP outcomes, studies on lens opacity were limited to assessing the effects of Fluticasone or Ciclesonide and their relation to presence of cataract (in particular subcapsular cataract).
The outcomes for changes in lens opacity and occurrence of cataract are described in Table 5. The table demonstrates 
Risk of bias
Comprehensive reporting of study methodology was inconsistent amongst randomised control trials (RCTs) ( Table 7) .
Sequence generation randomization was reported but detail of sequence generation given in 50% (20, 21, 23, 27, 30) . All studies reported blind evaluators but only two reported details of methods implemented to ensure blinding (22, 30) . One study was open to patients (30) , however this study attempted to exclude patient bias by assessing evaluator outcomes only. All studies except one (22) , reported on concealment and allocation. Complete outcome data was reported in all but one (29) . Two studies (20, 29) failed to report outcome data on withdrawals. Half of the studies were sponsored by pharmaceutical companies (27) (28) (29) (30) (31) with remaining studies did not report any conflict of interest.
Discussion
The changes in lens opacity and ocular hypertension from corticosteroids, administered orally, intravenous and, to a lesser degree, inhaled, are well documented. Prolonged exposure to the corticosteroids via any of these routes can result in intraocular pressure related visual loss or cataract (12, 25, 29, 33, 34) . The adverse profile of the corticosteroids, results largely from systemic absorption of the drug regardless of delivery type (4) . However, the occurrence of similar adverse events from intranasal delivery of the steroids remains controversial (12, 25, 33) . The literature is replete with non-systematic reviews on the subject (n = 116) with 42% (n = 8) of all original study representing case series only. In recent years, a rising trend of case reports and narrative literature reviews warn of the potential of INCS to cause ocular hypertension, worsening of preexisting glaucoma and changes in lens opacity, however, few offer more than level 4/5 data to support their recommendations. Such comments and case series/report data can lead to and environment of fear and subsequent poor prescribing patterns of intranasal steroids by primary care physicians (10-13, 29, 36) .
The established success of INCS in treatment of upper airway inflammatory disease has led to increased long term prescribing patterns by specialists and recommendations for long-term use (16, 18) . The intranasal formulations are designed to allow direct local delivery of the drug to the target area, whilst minimizing the risk of systemic absorption (4, 29) . The latest generation of INCS, such as Fluticasone propionate, Mometasone furoate, Ciclesonide, and Fluticasone furoate come close to the ideal INCS, in terms of the pharmacokinetic or pharmacodynamics properties. They have a high degree of glucocorticoid receptor affinity, potency and specificity; as well as low systemic bioavailability, high rate of hepatic first-pass metabolism and therefore rapid systemic elimination. Moreover, the slow-release drug-lipid complexes allow clinically desirable outcome with once-daily dosing (9, 37) . This is all, in addition to remaining very successful in achieving the clinical efficiency by reducing mucosal swelling, improving sinus drainage and therefore hastening elimination of pathogens, and inhibiting the release and formation of mucous secretogogues (4, 5, 25, 33) .
In 1960, Black et al. (38) , first described the association between systemic corticosteroids and the development of posterior Later reports such as Kewlery et al. (39) , and Cumming et al. (40) , confirmed similar association with the use of inhaled corticosteroids. However, intranasal steroids do vary significantly in their systemic absorption, bioavailability, and lipophilicity, to the corticosteroids administered via other routes (4) . With intranasal delivery, up to 30% of the dose is deposited and remain in the nose depending on the drug's lipophilicity; the remainder is swallowed. Ninety-nine percent of the swallowed INCS is subject to the first-pass metabolism in the liver for second-generation agents. Hence, the systemic side effect from INCS depends on not only the lipophilicity of the administered corticosteroid and direct absorption via the nasal mucosa, but also its systemic and local bioavailability, and hepatic first-pass metabolism (4, 9, 13, 25, 36, 37) . Whereas, inhaled corticosteroids, which have been linked to systemic adverse events, are primarily absorbed through the respiratory mucosa of the lower airway. And although, oropharyngeal deposition may occur, only a fraction is swallowed and undergoes hepatic first-pass metabolism. The remainder is absorbed systemically (9, 37, 41) . Doses used in the lower airway are traditionally much larger than those used intranasally.
Fraunfelder et al. (36) , argues that nasal steroids can reach ocular structures in levels sufficient to cause ocular hypertension and posterior subcapsular cataract in susceptible patients. This study had identified 21 patients who had PSC following administration of nasal or inhaled Beclomethasone. Most of the patients were on the medication for more than five years and often in higher than recommended dose of 252 mcg/day. Most importantly, 9
out of 21 patients were also using systemic steroids concomitantly. The concomitant use of systemic steroids in a large number of the patients, in these studies, is a significant confounding factor. Eight years later, Ozturk et al. (14) , demonstrated a lack of any considerable change in the lens opacity of all patients studied, despite using higher dose of nasal Beclomethasone (400 mcg/day) for over 19 months.
This systematic review found no difference in intraocular pressure or diagnosis of glaucoma in 4376 patients across 10 randomised control trials (20) (21) (22) (23) (26) (27) (28) (29) (30) (31) , exposed to a range of intranasal steroids (including new and old generation INCS) from 2-104 weeks, between controls and INCS users. Therefore, level one evidence supports a low risk for INCS use in the management of upper airway inflammatory disease. With a varying duration of INCS from 2 weeks to 2 years, IOP changes can occur within these time frames. IOP changes can be seen within hours after a parenteral dose of corticosteroid (42) and current recommendations within the ophthalmic literature suggests a 2 week review of IOP when patients commence non-parenteral exogenous corticosteroid use (43) . There were 5 studies that included patients with glaucoma or ocular hypertension in their analysis. Four of these studies were RCTs (22, 23, 29, 30) and one case control (1) . All five studies concluded that INCS does not worsen existing ocular hypertension or glaucoma.
This review also found that there was no difference in lens opacification or the new diagnosis of cataracts between INCS users and control group in 3014 patients across 6 randomised control trials (26) (27) (28) (29) (30) (31) , following exposure to Ciclesonide or Fluticasone for 6 to 104 weeks. Therefore, level one evidence supports INCS as a safe treatment of upper airway inflammatory disease, and does not appreciably increase the risk of cataract in patients exposed to this medication for a considerably long period of time.
Meta-analysis of the data was not possible, as almost all studies reviewed in this systematic review, reported zero adverse ocular outcomes. This is an obvious limitation of our study as the zero adverse effects can either represent the absence of a true effect or an underpowered study, however the risk is likely to be very small. 
Conclusion
